Preclinical studies showed that the downregulation of DNM2, whose levels are increased also in BIN1 and MTM1-related centronuclear myopathies, resulted in clinical and histological improvements [311, 316]. Here, DNM2 is linked to autosomal dominant centronuclear myopathy.